Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

Full description

Bibliographic Details
Main Authors:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2021

Similar Items

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
by: de Vlam, K, et al.
Published: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
by: de Vlam, K, et al.
Published: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
by: Taylor, P, et al.
Published: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
by: Taylor, PC, et al.
Published: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
by: Dougados, M, et al.
Published: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
by: Iain B McInnes, et al.
Published: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Dougados, M, et al.
Published: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
by: Maxime Dougados, et al.
Published: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Gladman, DD, et al.
Published: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
by: Taylor, PC, et al.
Published: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
by: Coates, L, et al.
Published: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
by: Kristensen, LE, et al.
Published: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
by: Philip J. Mease, et al.
Published: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Taylor, P, et al.
Published: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
by: Daniela Graham, et al.
Published: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
by: Dafna D. Gladman, et al.
Published: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
by: Laura C. Coates, et al.
Published: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
by: Peter C. Taylor, et al.
Published: (2022-07-01)

Measuring outcomes in psoriatic arthritis
by: Ogdie, A, et al.
Published: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
by: Alexis Ogdie, et al.
Published: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
by: Lars Erik Kristensen, et al.
Published: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
by: Nash, P, et al.
Published: (2020)

Psoriatic arthritis
by: FitzGerald, O, et al.
Published: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
by: Victoria Navarro-Compán, et al.
Published: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
by: Ogdie, A, et al.
Published: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
by: Marta Skorupska, et al.
Published: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
by: Taylor, PC, et al.
Published: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
by: Philip J Mease, et al.
Published: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
by: Philip J Mease, et al.
Published: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
by: Taylor, P, et al.
Published: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
by: Kevin L. Winthrop, et al.
Published: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
by: Lars E. Kristensen, et al.
Published: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
by: Nash, P, et al.
Published: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
by: Burmester, GR, et al.
Published: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
by: Ly K, et al.
Published: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
by: Nash, P, et al.
Published: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
by: Gerd R. Burmester, et al.
Published: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
by: Peter Nash, et al.
Published: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
by: Leung, Y, et al.
Published: (2018)